Leadership Changes and Legal Challenges in Medicare Operations

Health Secretary Robert F. Kennedy Jr. has announced significant changes to the leadership team at the Department of Health and Human Services (HHS). Chris Klomp, the Director of Medicare, will now oversee all HHS operations, retaining his roles at the Centers for Medicare and Medicaid Services (CMS) where he has been instrumental in negotiating lower drug prices under the Inflation Reduction Act. Kennedy's restructuring also includes appointing Kyle Diamantas and Grace Graham as senior counselors at the Food and Drug Administration (FDA), alongside other key personnel changes aimed at enhancing coordination within HHS.

Politico

In February 2026, the HHS Office of Inspector General (HHS-OIG) issued the Medicare Advantage Industry Compliance Program Guidance (ICPG), which provides updated recommendations for compliance across the Medicare Advantage (MA) sector. This guidance is crucial as MA now encompasses over half of all Medicare beneficiaries, representing a significant portion of Medicare spending. The ICPG addresses compliance risks such as access to care, marketing practices, risk adjustment, and oversight of third-party activities, emphasizing the need for robust compliance programs to mitigate scrutiny and ensure high-quality care.

National Law ReviewPolitico

AbbVie Inc. has filed a lawsuit against HHS, contesting the inclusion of its Botox product in the Medicare Drug Price Negotiation Program. AbbVie argues that the selection violates the Inflation Reduction Act's explicit exclusion of plasma-derived products from price negotiations. The company claims that Botox, which contains ingredients sourced from human blood plasma, should not have been selected for price negotiations set to take effect in 2028. AbbVie’s lawsuit highlights broader concerns within the pharmaceutical industry regarding the constitutionality of the negotiation program, echoing similar legal challenges from other drug manufacturers.

AbbVie Sues HHS Over Selection of Botox for Medicare Price CutsFiercePharmaNational Law Review

The restructuring of HHS leadership and the issuance of the Medicare Advantage ICPG have drawn mixed reactions. Critics argue that the changes may not adequately address the complexities and compliance challenges faced by MA organizations. Additionally, AbbVie's lawsuit reflects a growing frustration among pharmaceutical companies regarding the implications of the Inflation Reduction Act on their products. The legal arguments presented by AbbVie, including claims of constitutional violations, are part of a broader trend of litigation against the drug pricing reforms initiated under the Biden administration.

AbbVie Sues HHS Over Selection of Botox for Medicare Price Cuts

As HHS implements these leadership changes and compliance guidelines, the agency is expected to face ongoing scrutiny from both industry stakeholders and regulatory bodies. The outcome of AbbVie's lawsuit could set a significant precedent for future negotiations and the interpretation of the Inflation Reduction Act. Stakeholders in the healthcare sector will be closely monitoring these developments as they unfold, particularly in light of the upcoming price negotiations for Botox and other selected drugs.

AbbVie Sues HHS Over Selection of Botox for Medicare Price Cuts

• “The company alleges the selection of Botox violates the Administrative Procedure Act, forces it to turn over the product to Medicare beneficiaries without just compensation in violation of the takings clause, and requires it to express an “untrue statement” that it has acceded to a fair price in violation of the First Amendment.” — AbbVie Inc.

AbbVie Sues HHS Over Selection of Botox for Medicare Price Cuts

• “Key Takeaways With MA at the forefront of enforcement, and with HHS-OIG’s Medicare Advantage ICPG now providing detailed, sector specific guidance, compliance has never been more important for MAOs as well as providers, marketers, and vendors that support MA operations.” — HHS-OIG Guidance Document.

National Law Review

• “obviously disappointed that [Botox] was selected given that it’s a plasma-derived product and should have been excluded.” — Robert Michael, CEO of AbbVie.

FiercePharma